Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 4/20 | 0.33 |
| ▸ | QPCT | Q16769 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044406 | 0.84 | MAOA (0.38) | MAOASTING1MAOB | |
| SCHEMBL5764719 | 0.77 | MAOA (0.65) | MAOASTING1MAOBTSHRF10 | |
| SCHEMBL3043513 | 0.77 | FADS1 (0.36) | FADS1TSHR | |
| SCHEMBL3043319 | 0.76 | MAOA (0.40) | MAOAMAOBFADS1F10 | |
| SCHEMBL3043449 | 0.75 | MAOA (0.37) | MAOAMAOBFADS1 | |
| SCHEMBL5725958 | 0.73 | MAOA (0.52) | MAOAMAOBFADS1F10 | |
| SCHEMBL3041136 | 0.72 | MAOA (0.78) | MAOAMAOBF10 | |
| SCHEMBL6040286 | 0.72 | MAOA (0.78) | MAOAMAOBF10 | |
| SCHEMBL3045670 | 0.72 | MAOA (0.60) | MAOAMAOBF10 | |
| SCHEMBL3043441 | 0.72 | MAOA (0.60) | MAOAMAOBFADS1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885STING1 2901/4885MAOB 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.